Key facts
- It has raised $73.0M; the latest was Early Stage VC ($65.0M) in Jul 2024.
- Notable investors include New Enterprise Associates, OrbiMed, Bayshore Global Management, BioGeneration Ventures, Torrey Pines Investment — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Brenig Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Brenig Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Brenig Therapeutics
Operator of a drug development company intended to utilize an AI/ML approach through clinical candidates across multiple therapeutic areas. The company is redefining the frontier of aging science with a resolute focus on addressing neurodegeneration and translating groundbreaking research into transformative therapies, enabling drug discovery companies to defeat neurodegenerative diseases.
- Sector
- Healthcare
- HQ
- Somerville, MA, United States
- Founded
- 2021
- Website
- brenigther.com/
- Ownership
- Privately Held (backing)
Brenig Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Brenig Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Brenig Therapeutics in its N-PORT filings yet. We sweep new filings monthly.